How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers

• Bente Glintborg,
• Johan Askling,
• Dan Nordström,
• Katerina Chatzidionysiou,
• Lene Dreyer,
• Thomas Frisell,
• Bjorn Gudbjornsson,
• Gerður Gröndal,
• Kalle Aaltonen,
• Bénédicte Delcoigne,
• Merete L Hetland,
• René Cordtz,
• Kristian Zobbe,
• Nina Trokovic,
• Sella Aarrestad Provan

Affiliations

Bente Glintborg

Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

Johan Askling

Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Karolinska Institutet Department of Medicine Solna, Stockholm, Sweden

Dan Nordström

Department of Medicine and Rheumatology, Helsinki University Central Hospital, Helsinki, Uusimaa, Finland

Katerina Chatzidionysiou

Rheumatology Unit, Department of Medicine, Solna, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden

Lene Dreyer

Center of Rheumatic Research Aalborg (CERRA), Department of Rheumatology, Aalborg Universitetshospital, Aalborg, Denmark

Thomas Frisell

Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

Bjorn Gudbjornsson

Centre for Rheumatology Research, University Hospital, and Faculty of Medicine, University of Iceland, Reykjavik, Iceland

Gerður Gröndal

17 Centre for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland

Kalle Aaltonen

On behalf of the ROB-FIN registry, Helsinki, Finland

Bénédicte Delcoigne

Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

Merete L Hetland

DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark

René Cordtz

Center for Rheumatology and Spine Diseases, Rigshospitalet, Gentofte Hospital, The Parker Institute, Frederiksberg Hospital Parker Institute, Frederiksberg, Denmark

Kristian Zobbe

1Bispebjerg and Frederiksberg Hospital, The Parker Institute, Frederiksberg, Denmark

Nina Trokovic

EuroSpA Research Collaboration, on behalf of DANBIO (Denmark), ARTIS (Sweden), SCQM (Switzerland), NOR-DMARD (Norway), ATTRA (Czech Republic), Reuma.pt (Portugal), BIOBADASER (Spain), ROB-FIN (Finland), biorx.si (Slovenia), ICEBIO (Iceland), TURKBIO (Turkey), RRBR (Romania), ARC (Netherlands), BSRBR-AS (UK), GISEA (Italy), Denmark

Sella Aarrestad Provan

Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway